JEFFS ROGER 4

What Happened
Roger Jeffs, a director of Axsome Therapeutics (AXSM), reported conversion of 1,429 restricted stock units (RSUs) into 1,429 shares on June 8, 2026 (transaction code M—exercise/conversion of a derivative). The Form 4 shows an acquisition of 1,429 shares (price N/A) and a simultaneous disposition of 1,429 shares at $0.00. No cash purchase or open-market sale value is reported.

Key Details

• Transaction date: 2026-06-08 (reported on Form 4 filed 2026-06-10).
• Transaction codes: M (exercise/conversion of derivative).
• Reported activity: +1,429 shares acquired via RSU conversion; 1,429 shares disposed at $0.00.
• Shares owned after transaction: not specified in the excerpt of the filing.
• Footnotes: F1 — 1,429 RSUs were granted on 2026-06-06 and vested at the one-year anniversary of the grant; F2 — RSUs convert into common stock on a one-for-one basis.
• Filing timeliness: filed within the typical two-business-day window (not indicated as late).

Context
This was a routine equity-compensation conversion (RSUs vesting and converting to common stock) rather than an open-market buy or sale. The matching $0.00 disposition is shown on the Form 4 but not explained; such dispositions in RSU conversions are commonly used to satisfy tax-withholding or company retention obligations, though the filing does not specify the reason. As a director (not a 10% owner), this transaction reflects standard compensation mechanics rather than a direct buy/sell decision.